| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.46B | 1.45B | 1.42B | 1.39B | 733.04M | 442.89M |
| Gross Profit | 347.65M | 366.12M | 354.27M | 382.28M | 124.79M | -50.87M |
| EBITDA | 239.00M | 306.40M | 274.58M | 238.40M | 124.83M | -74.93M |
| Net Income | -98.44M | -4.24M | -78.02M | -87.17M | -184.86M | -391.73M |
Balance Sheet | ||||||
| Total Assets | 5.55B | 5.69B | 5.82B | 6.13B | 6.26B | 6.08B |
| Cash, Cash Equivalents and Short-Term Investments | 223.16M | 206.65M | 183.75M | 41.04M | 58.52M | 124.27M |
| Total Debt | 2.57B | 2.57B | 2.64B | 2.71B | 2.76B | 2.79B |
| Total Liabilities | 2.95B | 2.91B | 2.97B | 3.05B | 3.10B | 2.81B |
| Stockholders Equity | 2.51B | 2.70B | 2.76B | 3.00B | 3.16B | 3.26B |
Cash Flow | ||||||
| Free Cash Flow | 370.38M | 275.00M | 236.20M | 162.00M | -13.06M | -326.79M |
| Operating Cash Flow | 287.70M | 275.00M | 236.20M | 278.75M | 70.77M | -201.78M |
| Investing Cash Flow | -78.92M | -92.83M | 142.02M | -109.39M | -81.57M | 250.12M |
| Financing Cash Flow | -120.93M | -158.22M | -236.85M | -209.34M | -33.25M | 31.08M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | $2.94B | 16.94 | 5.41% | 8.30% | 0.57% | -13.58% | |
65 Neutral | $2.17B | 12.19 | 3.79% | 4.94% | 3.15% | 1.96% | |
65 Neutral | $1.88B | 35.44 | 3.98% | 5.13% | 0.95% | -8.40% | |
64 Neutral | $1.42B | 26.71 | 4.58% | 3.71% | 4.29% | 141.01% | |
58 Neutral | $1.17B | 160.87 | 1.49% | 7.76% | -0.58% | -83.32% | |
57 Neutral | $1.76B | 1,023.91 | 0.88% | 3.98% | 3.04% | -98.77% | |
54 Neutral | $1.36B | -10.07 | -3.74% | 0.34% | 0.99% | -360.58% |
Pebblebrook Hotel Trust announced on December 18, 2025, that it plans to release its financial and operating results for the quarter ended December 31, 2025, after U.S. markets close on February 25, 2026, followed by a quarterly earnings conference call and webcast on February 26, 2026, at 9:00 a.m. Eastern time. The scheduled disclosure and investor call underscore the REIT’s ongoing engagement with shareholders and analysts, providing an upcoming checkpoint on the company’s operating performance and portfolio trends across its U.S. urban and resort lifestyle hotel assets.
The most recent analyst rating on (PEB) stock is a Hold with a $11.00 price target. To see the full list of analyst forecasts on Pebblebrook Hotel stock, see the PEB Stock Forecast page.
On December 15, 2025, Pebblebrook Hotel Trust announced that its Board of Trustees authorized and declared cash dividends for its common and preferred shares for the fourth quarter of 2025. The declared dividends include $0.01 per common share and varying amounts for its Series E, F, G, and H preferred shares, with payments scheduled for January 15, 2026. This decision reflects the company’s ongoing commitment to returning value to its shareholders and may impact its financial positioning and stakeholder interests.
The most recent analyst rating on (PEB) stock is a Hold with a $11.00 price target. To see the full list of analyst forecasts on Pebblebrook Hotel stock, see the PEB Stock Forecast page.
On December 3, 2025, Pebblebrook Hotel Trust completed the sale of the 752-room Westin Michigan Avenue Chicago for $72.0 million. The proceeds from this sale will be used to reduce outstanding debt and preferred equity, repurchase common shares, and support other capital allocation priorities. This transaction, along with a previous sale, has allowed the company to reduce its debt by $100 million. Despite the sale, Pebblebrook’s updated fourth-quarter and full-year 2025 outlook remains largely unchanged, as the reduction in interest expenses is expected to offset the loss of hotel-level EBITDA.
The most recent analyst rating on (PEB) stock is a Hold with a $13.00 price target. To see the full list of analyst forecasts on Pebblebrook Hotel stock, see the PEB Stock Forecast page.
On November 19, 2025, Pebblebrook Hotel Trust completed the sale of the 133-room Montrose at Beverly Hills in West Hollywood, California, for $44.25 million. The proceeds from this sale are intended for general corporate purposes, such as reducing outstanding debt, repurchasing shares, and supporting other capital allocation priorities to enhance long-term shareholder value. This transaction is not expected to affect the company’s current fourth-quarter or full-year 2025 outlook. Additionally, Pebblebrook has another hotel under contract for sale at $72 million, expected to close in the fourth quarter, subject to customary conditions.
The most recent analyst rating on (PEB) stock is a Sell with a $11.50 price target. To see the full list of analyst forecasts on Pebblebrook Hotel stock, see the PEB Stock Forecast page.
On October 21, 2025, Pebblebrook Hotel‘s Board authorized a new share repurchase program of up to $150 million, terminating the previous program. This initiative allows the company to buy back shares at its discretion, based on various market and economic factors, without a set expiration date, potentially impacting the company’s stock value and shareholder returns.
The most recent analyst rating on (PEB) stock is a Hold with a $11.50 price target. To see the full list of analyst forecasts on Pebblebrook Hotel stock, see the PEB Stock Forecast page.